The key catalyst is the late-breaking oral presentation of PYNNACLE Phase 2 data at ENA 2026 and the Q1 2027 NDA submission for accelerated approval. Monitor for any efficacy or safety signals from the full dataset that could affect the NDA's likelihood of acceptance.
Drug in focus
PMVP drug pipeline →rezatapopt
▲ Bullish Named in this 8-K- Impact
- Phase
- Phase 2 (pivotal)
- Time to market
- NDA submission planned for Q1 2027 under accelerated approval pathway. If accepted and approved under standard review timelines, potential FDA decision could come in late 2027 or early 2028.
- Next catalyst
- NDA filing · Q1 2027
What to watchThe next catalyst is the late-breaking oral presentation of updated PYNNACLE Phase 2 data at ENA 2026 on November 20, 2026, roughly 9 days away. Positive data could reinforce the NDA submission narrative and support the stock, while disappointing results (weaker efficacy or safety signals) could undermine the accelerated approval path. The NDA submission itself, planned for Q1 2027, is the next major binary event after ENA.
How the stock moved after the report
NEUTRAL VIEWSTOCK AT ENTRY AT T+5- T+0 · Nov 10 $1.22entry
- T+1 · 11d ago +3.28%α +1.96% · $1.26
- T+5 · 5d ago 0.00%α +2.33% · $1.22
- T+8 · todayOpen
- T+20 · in 17d Pending
- T+60 · in 3mo Pending
Price Chart
How similar events traded
Executive Summary
PMV Pharma reported Q3 2026 net loss of $34.4M, wider than the $21.1M loss in Q3 2025, driven by a $12.8M non-cash warrant liability charge from the August 2026 $50M public offering. The company highlighted an ORR of 46% in the pivotal Phase 2 PYNNACLE trial for rezatapopt in TP53 Y220C ovarian cancer, with an NDA submission planned for Q1 2027. Cash of $108.5M extends runway into Q1 2028.
Key Financial Metrics
Key Facts
- Net loss for Q3 2026 was $34.4M vs $21.1M in Q3 2025, primarily due to a $12.8M non-cash loss from change in fair value of warrant liability and $2.3M offering costs allocated to the warrant liability.
- Cash, cash equivalents, and marketable securities were $108.5M as of September 30, 2026, providing expected cash runway into Q1 2028.
- Closed an oversubscribed $50M public offering of securities in August 2026.
- Pivotal Phase 2 PYNNACLE trial data for rezatapopt showed an ORR of 46% (35/76 patients) in platinum-resistant/refractory ovarian cancer, with median time to response of 1.3 months and median duration of response of 10.0 months.
- NDA submission for rezatapopt in platinum-resistant/refractory ovarian cancer planned for Q1 2027.
- R&D expenses decreased to $16.1M from $18.2M year-over-year.
- Appointed Matt Eckler, Ph.D., to Board of Directors and Philip Herman as Chief Commercial Officer.
Financial Impact
Net loss widened by $13.3M YoY to $34.4M, but operating loss improved to $20.1M from $22.5M. Cash position increased to $108.5M from $79.4M at June 30, 2026, following the $50M offering.
Risk Factors
- Net loss increased significantly due to non-cash warrant liability charges from the August 2026 offering.
- The company is pre-revenue and depends on successful NDA submission and FDA approval of rezatapopt.
- Clinical trial results may not support accelerated approval; the NDA is based on a single-arm Phase 2 study.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-454467 |
| Document: pmvp-20261110.htm | 0001193125-26-454467 |
| Document: 0001193125-26-454467-index-headers.html | 0001193125-26-454467 |
| Document: 0001193125-26-454467-index.html | 0001193125-26-454467 |
| Document: 0001193125-26-454467.txt | 0001193125-26-454467 |
| 8-K Data (Synthetic) | 0001193125-26-454467 |
Track record
14 reports on PMVP
3 of 7 bullish or bearish reports moved the stock their way by T+20. Best: +29.46% at T+20 after the Aug 31, 2026 report. 5 of 7 went positive at some point.
Filters
- Nov 20, 20261d ago Press Release Bullish 7/10 Entry $1.20 Now $0.8760 −27.00% settles Dec 21
- Nov 16, 20265d ago SC 13G/A Neutral 3/10 Entry $1.22 Now $0.8760 −28.20% settles Dec 16
- Nov 10, 202611d ago 8-K Neutral 5/10 Viewing Entry $1.22 Now $0.8760 −28.20% settles Dec 9
- Oct 5, 20266w ago 8-K Bullish 6/10 Entry $1.78 to $1.31 Now $0.8760 −50.79% ▼ −26.40% −23.94% vs SPY
- Aug 31, 202611w ago Press Release Bearish 8/10 Entry $1.29 to $1.67 Now $0.8760 +32.09% ▼ −29.46% −29.14% vs SPY
- Aug 31, 202611w ago 8-K Bullish 7/10 Entry $1.29 to $1.67 Now $0.8760 −32.09% ▲ +29.46% +29.14% vs SPY
- Aug 31, 202611w ago Press Release Bearish 6/10 Entry $1.29 to $1.67 Now $0.8760 +32.09% ▼ −29.46% −29.14% vs SPY
- Aug 31, 202611w ago Press Release Bullish 8/10 Entry $1.29 to $1.67 Now $0.8760 −32.09% ▲ +29.46% +29.14% vs SPY
- Aug 14, 202614w ago 8-K Neutral 5/10 No price data
- Aug 14, 202614w ago Press Release Bullish 6/10 Entry $1.26 to $1.46 Now $0.8760 −30.48% ▲ +15.87% +17.86% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers